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Abstract: Importance: Short-term infusions of single vasodilators, usually given in a fixed dose, have not
improved outcomes in patients with acute heart failure (AHF). Objective: To evaluate the effect of a
strategy that emphasized early intensive and sustained vasodilation using individualized up-titrated doses
of established vasodilators in patients with AHF. Design, Setting, and Participants: Randomized, open-
label blinded-end-point trial enrolling 788 patients hospitalized for AHF with dyspnea, increased plasma
concentrations of natriuretic peptides, systolic blood pressure of at least 100 mm Hg, and plan for treat-
ment in a general ward in 10 tertiary and secondary hospitals in Switzerland, Bulgaria, Germany, Brazil,
and Spain. Enrollment began in December 2007 and follow-up was completed in February 2019. Interven-
tions: Patients were randomized 1:1 to a strategy of early intensive and sustained vasodilation throughout
the hospitalization (n = 386) or usual care (n = 402). Early intensive and sustained vasodilation was a
comprehensive pragmatic approach of maximal and sustained vasodilation combining individualized doses
of sublingual and transdermal nitrates, low-dose oral hydralazine for 48 hours, and rapid up-titration of
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or sacubitril-valsartan. Main
Outcomes and Measures: The primary end point was a composite of all-cause mortality or rehospitaliza-
tion for AHF at 180 days. Results: Among 788 patients randomized, 781 (99.1%; median age, 78 years;
36.9% women) completed the trial and were eligible for primary end point analysis. Follow-up at 180 days
was completed for 779 patients (99.7%). The primary end point, a composite of all-cause mortality or
rehospitalization for AHF at 180 days, occurred in 117 patients (30.6%) in the intervention group (includ-
ing 55 deaths [14.4%]) and in 111 patients (27.8%) in the usual care group (including 61 deaths [15.3%])
(absolute difference for the primary end point, 2.8% [95% CI, -3.7% to 9.3%]; adjusted hazard ratio, 1.07
[95% CI, 0.83-1.39]; P = .59). The most common clinically significant adverse events with early intensive
and sustained vasodilation vs usual care were hypokalemia (23% vs 25%), worsening renal function (21%
vs 20%), headache (26% vs 10%), dizziness (15% vs 10%), and hypotension (8% vs 2%). Conclusions
and Relevance: Among patients with AHF, a strategy of early intensive and sustained vasodilation, com-
pared with usual care, did not significantly improve a composite outcome of all-cause mortality and AHF
rehospitalization at 180 days. Trial Registration: ClinicalTrials.gov Identifier: NCT00512759.
DOI: https://doi.org/10.1001/jama.2019.18598
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IMPORTANCE Short-term infusions of single vasodilators, usually given in a fixed dose, have
not improved outcomes in patients with acute heart failure (AHF).
OBJECTIVE To evaluate the effect of a strategy that emphasized early intensive and sustained
vasodilation using individualized up-titrated doses of established vasodilators in patients
with AHF.
DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label blinded-end-point trial
enrolling 788 patients hospitalized for AHFwith dyspnea, increased plasma concentrations of
natriuretic peptides, systolic blood pressure of at least 100mmHg, and plan for treatment in
a general ward in 10 tertiary and secondary hospitals in Switzerland, Bulgaria, Germany,
Brazil, and Spain. Enrollment began in December 2007 and follow-up was completed in
February 2019.
INTERVENTIONS Patients were randomized 1:1 to a strategy of early intensive and sustained
vasodilation throughout the hospitalization (n = 386) or usual care (n = 402). Early intensive
and sustained vasodilation was a comprehensive pragmatic approach of maximal and
sustained vasodilation combining individualized doses of sublingual and transdermal nitrates,
low-dose oral hydralazine for 48 hours, and rapid up-titration of angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, or sacubitril-valsartan.
MAIN OUTCOMES ANDMEASURES The primary end point was a composite of all-cause
mortality or rehospitalization for AHF at 180 days.
RESULTS Among 788 patients randomized, 781 (99.1%; median age, 78 years; 36.9%women)
completed the trial and were eligible for primary end point analysis. Follow-up at 180 days
was completed for 779 patients (99.7%). The primary end point, a composite of all-cause
mortality or rehospitalization for AHF at 180 days, occurred in 117 patients (30.6%) in the
intervention group (including 55 deaths [14.4%]) and in 111 patients (27.8%) in the usual care
group (including 61 deaths [15.3%]) (absolute difference for the primary end point, 2.8%
[95% CI, −3.7% to 9.3%]; adjusted hazard ratio, 1.07 [95% CI, 0.83-1.39]; P = .59). Themost
common clinically significant adverse events with early intensive and sustained vasodilation
vs usual care were hypokalemia (23% vs 25%), worsening renal function (21% vs 20%),
headache (26% vs 10%), dizziness (15% vs 10%), and hypotension (8% vs 2%).
CONCLUSIONS AND RELEVANCE Among patients with AHF, a strategy of early intensive and
sustained vasodilation, compared with usual care, did not significantly improve a composite
outcome of all-cause mortality and AHF rehospitalization at 180 days.
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A
cute heart failure (AHF) is the most common di-
agnosis in the emergency department leading
to hospitalization.1,2 In contrast to the relevant
achievements in management of patients with chronic HF
with reduced left ventricular ejection fraction (LVEF), mor-
bidity and mortality remain unacceptably high in patients
with AHF.1
Early initiation of high-dose intravenous nitrates targeted
to arterial blood pressure vs high-dose furosemide and non-
invasive positive pressure ventilation improved outcomes in
severe pulmonary edema, an AHF phenotype representing
about 5% of all AHF cases.3,4 It is unknown, however,
whether early and aggressive vasodilation also provides ben-
efits in the broader AHF population. Short-term infusions of
single vasodilators, usually given in a fixed dose, did not
improve outcomes in several recent trials.5-7 Based on favor-
able safety data on the application of high-dose nitrates as
transdermal patches in patients treated in medical wards,8
the complementary hemodynamic profile of nitrates and
hydralazine,9-11 and the more pronounced benefits observed
in patients with chronic HF treated with high vs low doses of
angiotensin-converting enzyme (ACE) inhibitors and/or
angiotensin receptor blockers (ARBs),12,13 it was hypothesized
that a comprehensive pragmatic approach of early intensive
and sustained vasodilationmay improve long-term outcomes
in patients with AHF.
Methods
Study Design and Population
GALACTIC was an investigator-initiated, randomized, open-
label,blinded-end-point,multinational,multicenter study.The
open-label designwas selected for 2 reasons: first, to avoidun-
dertreatment in the placebo group of a blinded trial because
of concerns of treating physicians regarding the possible risk
of applying a second active drug and its associated increased
riskof adverse events, includinghypotension, in anacute con-
ditionwith an effective alternative therapy (loop diuretics) to
improve congestion5-7; second, to allow evaluation of a strat-
egy of rapid up-titration of the ACE inhibitor already in place
rather than that of a specific ACE inhibitor. The studywas car-
ried out according to the principles of the Declaration of Hel-
sinki and approved by the local ethics committees and the re-
spective national authorities.14 All patients provided written
informed consent. The trial protocol and the statistical analy-
sis plan are available in Supplement 1. Datamanagement and
randomizationwas overseenby the independent clinical trial
unitof theUniversityHospitalBasel,Basel, Switzerland (P.S.).15
Patients aged 18 years or older hospitalized for AHF were
eligibleregardlessof theirLVEF.ThediagnosisofAHFwasbased
on integrated clinical judgment according to clinical guide-
lines for each period2 and required New York Heart Associa-
tionclass III or IVdyspneaandelevatedB-typenatriureticpep-
tide (BNP) plasma concentrations of at least 500 ng/L or
N-terminal pro–B-type natriuretic peptide (NT-proBNP) con-
centrationsofat least2000ng/L.After theapprovalofsacubitril-
valsartan, the protocol was amended to specify that in pa-
tientsalreadytreatedwithsacubitril-valsartan,onlyNT-proBNP,
not BNP, could beused for the inclusion of patients and for de-
fining the up-titration scheme for sacubitril-valsartan.16,17
Patients who required immediate intensive care unit ad-
mission or urgent coronary intervention or who had a sys-
tolic bloodpressure lower than 100mmHgor severe renaldys-
function (creatinine>250μmol/L [>2.8mg/dL])wereexcluded
(a complete list of eligibility criteria is available in eTable 1 in
Supplement 2).
The final diagnosis of AHF was adjudicated by an inde-
pendent cardiologist who had access to all patients’ medical
records. In situationsofuncertainty about thediagnosis, cases
were reviewed and adjudicated in conjunctionwith a second
cardiologist (eAppendix in Supplement 2).
Randomization and Study Procedures
For central randomization in a 1:1 ratio to a strategy empha-
sizing early intensive and sustainedvasodilationorusual care
according tocurrentguidelines,2 stratificationaccording tosite
and BNP or NT-proBNP concentrations was performed using
static stratified block randomization schema with secuTrial
dedicated data management software (interActive Systems
GmbH) (eAppendix inSupplement2).18Early intensiveandsus-
tained vasodilation involved a comprehensive pragmatic ap-
proachofmaximal andsustainedvasodilationcombininghigh
and individualized doses of sublingual and transdermal ni-
trates, oral hydralazine for 48hours to avoidnitrate tolerance
and to complement thevasodilating effect of nitrates onveins
and large arterieswith that ofhydralazineon small arteries,9-11
and rapid up-titration of ACE inhibitors, ARBs, or sacubitril-
valsartanaccording topretreatmentand/orpreferenceof treat-
ing physicians, using a predefined safety corridor for systolic
blood pressure of 90 to 110mmHg (Box). To avoid further in-
creases in protocol complexity and the associated risk of re-
ducedprotocol adherence, no additional diastolic bloodpres-
sure targets were used.
Treatment was initiated with sublingual nitrates or nitro-
spray (0.8 mg glyceryl trinitrate at randomization and after
10 and 20minutes), followedbyhigh andmaximally tolerated
bloodpressure–adjusteddosesof transdermalnitrates (glyceryl
Key Points
Question Does a comprehensive approach of early intensive
and sustained vasodilation, using a combination of nitrates,
hydralazine, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, and sacubitril-valsartan, improve
outcomes in patients with acute heart failure?
Findings In this randomized clinical trial that included 788
patients hospitalized for acute heart failure, a strategy that
emphasized early intensive and sustained vasodilation, compared
with usual care, resulted in no significant difference in the primary
end point of 180-day all-cause mortality and acute heart failure
rehospitalizations (30.6% vs 27.8%, respectively).
Meaning Among patients with acute heart failure, a strategy of
comprehensive vasodilation, compared with usual care, did not
significantly improve a composite outcome of all-cause mortality
and acute heart failure rehospitalizations at 180 days.
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trinitrate) and rapid up-titration of ACE inhibitors, ARBs, or
sacubitril-valsartan(eFigure1 inSupplement2).2,12Onday3, the
transdermal nitrate dose was gradually decreased, while up-
titrationofACEinhibitors,ARBs,orsacubitril-valsartanwascon-
tinued until hospital discharge using the target doses recom-
mendedincurrentclinicalpracticeguidelinesforchronicHFwith
reduced LVEF.1,2 The transdermal application was chosen be-
cause itmaximizespatient safety inageneralmedicalwardset-
ting; for instance, in the case of arterial hypotension, themost
relevantadverseeffectofnitrates, thenitratepatchcaneasilybe
removed,with usually swift recovery of blood pressure.8 Indi-
vidualized doses of nitrateswere used, as the dose required to
lowerintracardiacfillingpressurestoarelevantextentvariessub-
stantiallyby individualpatient.19,20 In theusual caregroup,ni-
trateswere restricted to standard lowdoses, and the suggested
up-titrationofACEinhibitors,ARBs,or sacubitril-valsartandur-
ing hospitalizationwas slow. Postdischarge treatmentwas left
to the discretion of treating physicians.1,2
Therapies for AHF other than vasodilators, including di-
uretics,werenotaffectedbytheprotocolandwereprovidedac-
cording to guidelines and the discretion of treating physicians
in both groups.1,2 The protocol defined vasodilator treatment
in the intervention group until hospital discharge or day 7,
whichever came first. Up-titration of ACE inhibitors (or ARBs
or sacubitril-valsartan)until hospital dischargewas faster than
in the usual care group, so patients in the intervention group
were expected to receive a significantly higher dose of ACE in-
hibitors, ARBs, or sacubitril-valsartan at the time of discharge.
Itwas expected that in clinical practice thedifferencebetween
groups in the discharge dose of ACE inhibitors, ARBs, or sacu-
bitril-valsartanwould persist throughmost of the 180-day fol-
low-upperiod.12Thecombinationofmore rapid loweringof in-
tracardiac fillingpressuresbyhigh-dosenitratescombinedwith
hydralazine3,4,21 and higher doses of disease-modifying drugs
provenbeneficial inHFwithreducedLVEFthroughoutthestudy
period12,13 was expected to result in improved outcomes. The
trial protocol includedpredefineddeescalation schema incase
ofhypotensionor relevantworseningof renal functionandsug-
gested treatments forhypertension (Supplement 1andeTable2
in Supplement 2).
Outcomes
Theprimary endpointwas a composite of all-causemortality
or rehospitalization forAHFat 180days.An independent clini-
cal events committee, blinded to group assignment, centrally
adjudicated all deaths and hospitalizations through day 180.
Secondaryendpoints includedbutwerenot limited to the
individual components of the primary end point, a compos-
ite of all-causemortality or rehospitalizationdue to all causes;
time to discharge; blood pressure at days 1 through 7; quanti-
tative assessment of dyspnea at levels of 60° and 20° onday 2
and at discharge or on day 6, whichever came first, using a
5-point Likert scale ranging from“none” to “very severe”dys-
pnea; and NT-proBNP and creatinine concentrations at 48
hours (day 3) and at discharge. A full list of prespecified sec-
ondary end points is provided in eTable 3 in Supplement 2.22
Not all secondary end points are reported herein.
Post hoc analyses were conducted to characterize the
implementation of the early intensive and sustained vasodi-
lationstrategyanddosesofvasodilators, furosemide,andother
HF drugs during the course of hospitalization and at 180-day
follow-up, and to compare weight reduction during hospital-
ization. Patients and family physicians were contacted after
90daysand180daysbytelephoneor inwritten formbytrained
researchers. Further information was obtained by institu-
tional chart review and national registries on mortality.
Statistical Methods
Sample size was calculated for superiority hypothesis testing
basedonoutcomesobserved in apriorAHF study.23Ahypoth-
esized20%reductionofthecompositeendpointofdeathorAHF
rehospitalizationwithin180daysandaneventrateof48%inthe
Box. Strategy of Comprehensive Intensive
and Sustained Vasodilation
Day 1 (Treatment Initiation)
Sublingual (or as spray) glyceryl trinitrate, 0.8mg every
10minutes for 30minutes
Transdermal glyceryl trinitrate according to SBP (40-60mg every
24 hours if SBP 130mmHg; 60-80mg every 24 hours if SBP
>130mmHg)
Oral hydralazine, 25mg every 6 hours
After 6 hours, up-titration of transdermal glyceryl trinitrate
according to SBP (+20-40mg every 24 hours if SBP is
111-130mmHg; +20-60mg every 24 hours if SBP >130mmHg)
Day 2
Up-titration of transdermal glyceryl trinitrate according to SBP
(+20-40mg every 24 hours if SBP is 90-110mmHg; +20-60mg
every 24 hours if SBP is 111-130mmHg; +40-80mg every 24 hours
if SBP >130mmHg)
Oral hydralazine, 25mg every 6 hours
Initiation of ACE inhibitor, ARB, or ARN inhibitor therapy
(eg, ramipril, 1.25 mg/d, if SBP is 90-130mmHg; ramipril, 2.5 mg/d
if SBP >130mmHg); in case of preexisting ACE inhibitor, ARB,
or ARN inhibitor therapy, up-titration of dose according to therapy
schedule starting on day 2
Day 3
Gradual reduction of transdermal glyceryl trinitrate dose according
to SBP on day 3 (50% of day 2 if SBP is 90-130mmHg; 75% of day
2 if SBP is 131-150mmHg; 100% of day 2 if SBP >150mmHg) until
hospital discharge; intermittent dosing (12 hours with nitrates,
12 hours nitrate free) from day 3 onward
Up-titration of ACE inhibitor, ARB, or ARN inhibitor therapy
according to SBP (eg, ramipril, 2.5-3.75 mg/d, if SBP is
90-130mmHg; ramipril, 2.5-5 mg/d if SBP >130mmHg)
Days 4 Through 7
Up-titration of ACE inhibitor, ARB, or ARN inhibitor therapy
dependent on SBP until reaching themaximum daily
recommended dose (eg, ramipril, 10mg/d).2
ACE indicates angiotensin-converting-enzyme; ARB, angiotensin receptor
blocker; ARN, angiotensin receptor–neprilysin; SBP, systolic blood pressure.
The target SBP of 90-110mmHg for the entire hospitalization was
considered to represent themaximal feasible afterload reduction without
impairment of critical organ perfusion. The protocol included predefined
deescalation schema for hypotension, worsening renal function, and
uncontrolled hypertension (Supplement 1 and eTable 2 in Supplement 2).
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usual caregroupwasexpected to require385patientsper treat-
mentgroup toobtain,withaprobabilityof80%,a log-rank test
result thatwasstatisticallysignificantat the.05level.3,12Tocom-
pensate for an expected 1% to 2% of patients in whom the pri-
maryendpointcouldnotbeassessedat 180daysbecauseof loss




at the time of last known contact.
Patients were analyzed according to their randomization
group with inclusion of all randomized patients, irrespective
ofwhether and howmuch of the interventional strategy they
received. The primary end point was analyzed by using sur-
vival analysis for cumulative event rates including Kaplan-
Meier estimates and Cox regression for calculation of ad-
justed hazard ratios. Proportional hazards assumptions were
confirmed to have beenmet based onplots of log(time) vs log
(−log[survival]). The primary analysiswas adjusted for 4 pre-
defined strongpredictors of the composite primary endpoint
(deathorAHFrehospitalizationwithin180days): age,AHFhos-
pitalization in the year before inclusion, systolic blood pres-
sure, and serum creatinine level.24-26 In a post hoc analysis,
site effect was assessed by mixed-effects modeling with site
as a random effect. Interaction tests were conducted be-
tween the treatment group and the subgroup variables using
Coxregressionmodelswith tests for interaction toevaluate the
consistency of treatment effects. Prespecified subgroups are
described in the eAppendix in Supplement 2. No adjust-
ments for multiple comparisons were made; therefore, find-
ings for analyses of secondary end points should be inter-
preted as exploratory. All hypothesis testing was 2-sided and
P<.05wasregardedasstatisticallysignificant.SPSSversion25.0




FromDecember 10, 2007, to February 19, 2018, patientswere
enrolled in 10 centers in 5 countries. Patients were random-
ized amedian of 5.0 hours (interquartile range, 3.4-7.6 hours)
after presentation to the emergency department. Of the 788
patients randomized (Figure 1), 781 (99.1%) were eligible for
the analysis of the primary end point. The groups were well
balancedwith respect tobaseline characteristics (Table 1).Me-
dian agewas 78years, 37%werewomen, 59%had chronicHF,
median LVEFwas 36%, and coronary and hypertensive heart
disease were the most common underlying cardiac disor-
ders. Median time from onset of dyspnea to emergency de-
partmentpresentationwas6days.The last follow-upwascom-
pleted inFebruary2019, andcomplete clinical follow-upat 180
days was available in 779 patients (99.7%).
Primary End Point
Among781patients eligible for the analysis of theprimaryend
point, all-cause death or adjudicated AHF rehospitalization
through day 180 occurred in 117 patients (30.6%) in the early
intensive and sustained vasodilation group and in 111 pa-
tients (27.8%) in theusualcaregroup(absolutedifference,2.8%
[95% CI, −3.7% to 9.3%]; adjusted hazard ratio, 1.07 [95% CI,
0.83-1.39];P = .59) (Figure2). Thiswas confirmed inaposthoc
analysis using mixed-effects modeling with site as a random
effect (adjusted hazard ratio, 1.07; 95% CI, 0.83-1.39; P = .61)
(eTable 4 in Supplement 2).
Predefined subgroup analyses showed consistent results
in 7 of 8 subgroups including those defined by age and LVEF,
while indicating a statistically significant interaction of the
treatment effect according to sex (adjusted hazard ratio [fe-
male sex], 1.67; 95% CI, 1.08-2.59; P = .02 for interaction)
(Figure 3).
Key Secondary End Points
There was no significant difference in key secondary end
points, includingall-causedeaths throughday 180 (55 [14.4%]
with the intervention vs 61 [15.3%] with usual care; absolute
difference, 0.9%; 95% CI, −4.3% to 6.1%) and median length
of stay (9days inbothgroups; absolutedifference,0days;95%
CI, −1 to +1 day). Systolic and diastolic blood pressure initially
decreased more rapidly in the early intensive and sustained
vasodilation group, eg, to a systolic blood pressure on day 2
of 115 mmHg vs 125mmHg in the usual care group (absolute
difference, 10mmHg;95%CI,6-14mmHg;P < .001) (Figure4A
and eTable 5 in Supplement 2). There was no significant dif-
ference between blood pressure measurements on day 1 and
after day 3. Improvement of dyspnea, as assessed at levels of
60° and 20° on day 2 and day 6, and reduction of NT-proBNP
concentrationwerenot significantlydifferentbetweengroups
(eFigure 2 and eTables 6 and 7 in Supplement 2).
Figure 1. Flow of Participants Through the GALACTIC Trial
788 Patients randomizeda
386 Randomized to early intensive
and sustained vasodilation
384 Received intervention as
randomized
2 Did not receive intervention
1 Hypotension
1 Acute coronary syndrome
402 Randomized to usual care
401 Received usual care as
randomized
1 Did not receive usual
care (crossed over to
intervention group)
382 Included in primary analysis
4 Excluded
3 Informed consent form
not available at time of
monitoring visit
1 Consent fully withdrawn
399 Included in primary analysis
3 Excluded
1 Informed consent form
not available at time of
monitoring visit
2 Consent fully withdrawn
0 Withdrawn or lost to follow-up 1 Partial withdrawal of consent
on hospital day 2b
1 Partial withdrawal of consent
on day 90b
a The number of patients assessed for eligibility is not reported because it was
not collected at all sites.
bNo further follow-up data were obtained. All information up to withdrawal of
consent was used in analysis.
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Age, median (IQR), y 78.0 (70.0-85.0) 77.0 (69.0-84.0)
Sex
Female 140 (37) 148 (37)
Male 242 (63) 251 (63)
BMI, median (IQR) 26.5 (23.4-30.3) 26.6 (23.5-29.7)














<40 175 (52) 191 (54)
40-49 63 (19) 59 (17)
≥50 96 (29) 102 (29)
Cardiovascular risk factors
Hypertension 326 (85) 339 (85)
Ever smoked 197 (58) 209 (59)
Dyslipidemia 219 (57) 225 (56)
Diabetes mellitus 122 (32) 139 (35)
Structural heart disease
Chronic heart failure 231 (60) 229 (57)
Coronary artery disease 220 (58) 233 (58)
Hypertensive heart disease 177 (46) 174 (44)
Percutaneous coronary
intervention
105 (27) 107 (27)
Coronary bypass 78 (20) 89 (22)
Myocardial infarction 127 (33) 141 (35)
Valvular replacement 33 (9) 31 (8)
History of atrial fibrillation 192 (50) 200 (50)
Implantable cardioverter-
defibrillator
50 (13) 39 (10)
Cardiac
resynchronization therapy
27 (7) 22 (6)
Chronic comorbidities
COPD/asthma 83 (22) 88 (22)
Renal insufficiency 205 (54) 196 (49)
Serum creatinine,
median (IQR)
mg/dL 1.22 (0.96-1.55) 1.19 (0.94-1.58)
μmol/L 108.0 (85.0-136.8) 105.0 (83.5-139.5)
eGFR, median (IQR),
mL/min/1.73 m2c
51.5 (37.8-68.8) 52.9 (36.6-72.2)
Peripheral vascular disease 67 (18) 62 (16)
Stroke 64 (17) 66 (17)
Pneumonia 62 (16) 56 (14)
History of pulmonary
embolism
26 (7) 16 (4)
Liver disease 28 (7) 29 (7)
Active malignancy 14 (4) 10 (3)
Mental health disorder 44 (12) 57 (14)




III 208 (54) 218 (55)
IV 174 (46) 181 (45)
(continued)












Chest pain 93 (24) 105 (26)
Nocturia 211 (55) 242 (61)
Weight gain 189 (49) 193 (48)
Orthopnea 270 (71) 284 (71)
Paroxysmal
nocturnal dyspnea
211 (55) 218 (55)
Coughing 180 (47) 199 (50)
Sputum 106 (28) 100 (25)
Fever 14 (4) 18 (5)
Night sweats 49 (13) 58 (15)
Clinical examination
Heart murmur 145 (38) 157 (39)
Murmur radiation 47 (12) 46 (12)
Third heart sound 27 (7) 30 (8)
Positive hepatojugular
reflux
98 (26) 92 (23)
Jugular venous distension 197 (52) 190 (48)
Edema 287 (75) 280 (70)
Ascites 22 (6) 21 (5)
Pulmonary
attenuatione
87 (23) 66 (17)
Pulmonary
wheezing
86 (23) 85 (21)
Pulmonary rales 331 (89) 348 (90)







Systolic 130.0 (117.2-145.0) 131.0 (118.0-150.0)
















Triggers of current acute
heart failure episodef
Unknown 109 (29) 84 (21)
Arrhythmiag 102 (27) 103 (26)
Infection 56 (15) 48 (12)
Uncontrolled hypertension 40 (10) 53 (13)
Volume overload 35 (9) 42 (11)
Nonadherence
to medication




25 (7) 21 (5)
Medication (NSAIDs,
changes in diuretics)
24 (6) 32 (8)
Myocardial
ischemia/necrosis





21 (5) 23 (6)
(continued)
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Post Hoc Analyses
From days 1 to 5 and 1 to 3, respectively, doses of nitrates and
hydralazinewere significantlyhigher in theearly intensiveand
sustained vasodilation group compared with the usual care
group, eg, the median dose of nitroglycerin on day 2 was 60
mg in the intervention group vs 0mg in the usual care group
(absolute difference, 60 mg; 95% CI, 50-60 mg; P < .001)
(Figure 4, B-C). In contrast, on days 3 and 4, doses of furose-
mide equivalent were lower in the intervention group com-
pared with the usual care group (eg, the median dose on day
4 was 60 mg in the intervention group vs 80 mg in the usual
care group; absolute difference, 20 mg; 95% CI, 0-25 mg;
P = .04) (Figure 4D) andwere associatedwith a slower reduc-
tion in body weight (Figure 4F). From day 3 to hospital dis-
charge, up-titration of ACE inhibitors, ARBs, or sacubitril-
valsartan was significantly higher in the intervention group
compared with the usual care group, with a median absolute
increase of 12.5% of target dose (interquartile range, 0%-
50%) vs 0% of target dose (interquartile range, 0%-25%) (ab-
solutedifference, 12.5%;95%CI,0%-25%;P < .001) (Figure4E).
Other concomitantmedicationsusedduring the study inboth
groups are presented in eTables 8 and 9 in Supplement 2.
At 180days, 22%ofpatients in theearly intensive and sus-
tained vasodilation group vs 16% in the usual care group at-
tained the target dose of theprescribedACE inhibitor, ARB, or
sacubitril-valsartan (absolute difference, 6%; 95% CI, 0.3%-
11.6%;P = .04). Thepercentageofpatients receiving themedi-
cationsand theprescribedpercentageof the targetdoseatpre-
sentation, discharge, and 180days arepresented in eTables 10
and 11 in Supplement 2.
Adverse Events
The most common clinically significant adverse events fol-
lowingearly intensiveandsustainedvasodilationvsusual care,
respectively, were hypokalemia (23% vs 25%), worsening re-
nal function (21% vs 20%), headache (26% vs 10%), dizziness
(15% vs 10%), prolongation of index hospitalization (10% vs
6%), and hypotension (8% vs 2%) (Table 2).
Discussion
In this randomizedclinical trial that included788patientshos-
pitalized for AHF, a strategy that emphasized early intensive
and sustained vasodilation, compared with usual care, re-
sulted in no significant difference in the primary end point of
180-day all-causemortality and AHF rehospitalizations. This
trial has several unique features: it tested a comprehensive
strategyof early intensiveandsustainedvasodilationusing in-
dividualizeddosesofwell-characterized,widelyavailable, and
mostly inexpensive drugs, rather than a single novel andusu-
ally expensive drug at a fixed dose.
This study extends and corroborates findings fromprevi-
ous work on the treatment of patients with AHF, particularly
3 large phase 3 trials of novel vasodilators (neseritide, ularit-
ide, and serelaxin) andamoderate-size (n = 308) investigator-
initiateddirect comparisonofdiuretic strategies, all 4ofwhich
also provided neutral findings.5,7,29 Overall, these trials sug-
gest that short-term interventions such as vasodilation may
not influence long-term outcomes in the heterogeneous AHF
population, even when applying individualized and aggres-
sive dosing strategies as in this trial.5,7,29 Median time from
emergency department presentation to randomization was 5
hours in this study,whichwaseven shorter than that achieved
in the other 4 trials.5,7,29 Patients enrolled in this study were
representativeof thebroadAHFpopulationpresentingtoemer-
gency departments inNorthAmerica andEurope.6,30Median
LVEF in this study was 37% compared with amean of 39% in
a US registry and a mean of 39% in the phase 3 study of
serelaxin.6,30
Fromabroaderperspective, these trials alsosuggested that
pulmonarycongestion, although thehallmarkofAHF,maynot
be the ideal target for novel therapies. Part of the rationale for
a possible beneficial long-term effect of vasodilators in AHF
was to ameliorate pulmonary congestion without the estab-
lished detrimental effects of loop diuretics.5,7,29 Recently,
this rationale has been challenged by 2 lines of evidence:
first, long-term studies documenting that the beneficial ef-
fect of hemoconcentration (ie, effective decongestion) seems
tooffsetworsening renal function,31,32 and second, a random-
ized trial showing that the use of a stepped diuretic therapy
algorithm was superior to a strategy of ultrafiltration for the
preservation of renal function.33 In agreement with these re-
cent observations, this trial showed that early intensive and
sustained vasodilation did not lead to more rapid improve-
ment in dyspnea or more rapid reduction in NT-proBNP con-
centrations compared with usual care with its use of higher
doses of loop diuretics. Therefore, among AHF patients after
initial stabilization in the emergency department, relative to






Anemia (<100 g/L) 11 (3) 23 (6)
Alcohol 7 (2) 10 (3)
Dietary indiscretion 4 (1) 5 (1)
Thyroid disorders 5 (1) 2 (1)
Physical, emotional,
environmental stress
2 (1) 4 (1)
Myocarditis 0 2 (1)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); BNP, B-type natriuretic peptide; COPD, chronic
obstructive pulmonary disease; IQR, interquartile range; NSAID, nonsteroidal
anti-inflammatory drug; NT-proBNP, N-terminal pro–B-type natriuretic peptide.
a Data arepresentedas absoluteNo. (%)of participants unless otherwise indicated.
bTransthoracic echocardiography was performed using standard techniques
and left ventricular ejection fraction (LVEF) was calculated using the biplane
method of discs formula.
c Estimated glomerular filtration rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration formula.
dNewYork Heart Association (NYHA) symptom severity functional classes:
class I = no limitation during ordinary physical activity; class II = slight limitation
duringmoderate physical activity by dyspnea and/or fatigue; class III = marked
limitation of physical activity by symptomswithminimal exertion;
class IV = inability to carry out any physical activity without discomfort.
e Pulmonary attenuation defined as diminished breath sounds on auscultation
as a possible sign of pleural effusion, etc.
f Patients could havemore than 1 acute heart failure trigger.
gAtrial fibrillation, ventricular tachycardia, bradycardia, atrial ventricular block.
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Figure 2. Kaplan-Meier Estimates of the Primary End Point of Cumulative All-CauseMortality
or Acute Heart Failure RehospitalizationWithin 180Days Among Patients Treated

















































   sustained vasodilation
Early intensive and
   sustained vasodilation
Usual care
Usual care
Adjusted hazard ratio, 1.07 (95% CI, 0.83-1.39); P = .59
Median observation time, 180 days
(interquartile range, 136-180 days) in
the early intensive and sustained
vasodilation group vs 180 days
(interquartile range, 141-180 days) in
the usual care group.
Figure 3. Risk of All-Cause Death or Acute Heart Failure RehospitalizationWithin 180Days in Prespecified Subgroups Among Patients Treated








Adjusted Hazard Ratio (95% CI)
No. of Primary Composite End-Point
Events/Total No.
Early Intensive and Sustained
Vasodilation (n = 382)
Usual Care
(n = 399)Prespecified Subgroups
Adjusted Hazard
Ratio (95% CI) P Value
53/140 34/148Female 1.67 (1.08-2.59)
Sex
64/242 77/251Male 0.85 (0.61-1.19)
43/144 34/159<75 1.23 (0.78-1.95)
Age, y
74/238 77/240≥75 0.97 (0.70-1.34)
43/107 37/103<120 1.11 (0.71-1.72)
74/275 74/296≥120 1.05 (0.76-1.45)
56/175 44/191<40 1.34 (0.90-1.99)
LVEF, %
Systolic blood pressure at randomization, mm Hg
41/162 43/166No 0.94 (0.61-1.45)
76/220 68/233Yes 1.13 (0.82-1.57)
Known coronary artery disease
31/151 41/170No 0.81 (0.51-1.30)
86/231 70/229Yes 1.21 (0.88-1.66)
History of heart failure
36/145 37/158<1000 0.93 (0.59-1.48)
81/237 74/241≥1000 1.12 (0.82-1.54)
BNP concentration at randomization, ng/L
82/248 79/244<60 1.03 (0.75-1.40)
35/134 32/155≥60 1.26 (0.78-2.04)
117/382 111/399Total 1.07 (0.83-1.39)
eGFR at randomization, mL/min/1.73 m2
23/63 23/5940-49 0.89 (0.50-1.60)













BNP indicates B-type natriuretic peptide; eGFR, estimated glomerular filtration
rate; LVEF, left ventricular ejection fraction. Data on LVEF were not available for
47 of 399 patients in the usual care group and 48 of 382 patients in the
intervention group. BNPmeasurements were not available for 179 of 399
patients in the usual care group and 215 of 382 patients in the intervention
group. In those patients, the biological equivalent concentration of BNPwas
estimated as their N-terminal pro–BNP concentration × 0.2.
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Figure 4. Post Hoc Analysis of Medication Doses andWeight Reduction and Prespecified Exploratory Analysis of Blood Pressure in Early Intensive and Sustained Vasodilation vs Usual Care Groups
Daily Dose, mg
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Systolic and diastolic blood pressureA
Furosemide-equivalent doseaD
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARN, angiotensin
receptor–neprilysin. Yellow boxes indicate early intensive and sustained vasodilation; blue boxes, usual care.
Bars indicate medians; box bottoms and tops, 25th and 75th percentiles; whiskers, upper and lower adjacent
values; dots, outliers. Upper adjacent value is defined as the largest observation less than or equal to third quartile
+ 1.5 × interquartile range (IQR). Lower adjacent value is the smallest observation equal to first quartile − 1.5 × IQR.
Significant differences (P < .05) were found between groups for nitroglycerin doses throughout hospitalization,
for hydralazine doses from day 1 to day 3, for furosemide-equivalent doses on day 4, for ACE inhibitor, ARB, and
ARN inhibitor doses from day 3 to day of discharge, for systolic and diastolic blood pressure on day 2 and day 3,
and for weight reduction from day 2 to day 7.
a Furosemide-equivalent dose on day 1 corresponds to intravenous furosemide application and on day 2 through
180-day follow-up corresponds to prescribed furosemide and/or torasemide dose × 4.
bAbsolute increases of percentage target dose of ACE inhibitors, ARBs, and ARN inhibitors are reported starting
on day 2. Absolute decreases of percentage target dose are expressed as a negative number (eg, a decrease of
ramipril dose from 5mg/d to 2.5 mg/d corresponds to −25% absolute increase of percentage target dose of
ramipril at 10mg/d).
c Weight reduction is reported starting on day 2. In most patients, weight on day 1 was a self-reported estimate






































































































































































































intravenous loopdiuretics, the roleofacutevasodilationseems
to be smaller than previously thought.1,2 The lower doses of
loop diuretics used in the early intensive and sustained vaso-
dilation group may have led to the neutral results regarding
improvement in dyspnea and reduction of NT-proBNP con-
centrations. Theymayhave also at least in part contributed to
theneutraleffectondeathorAHFrehospitalizationat 180days.
Predefined, exploratory, hypothesis-generating subgroup
analysis foundastatistically significant interactionof the treat-
ment effect regarding the primary endpoint of all-cause death
or AHF rehospitalizationwith 1 of the 8 subgroups: sex, which
suggests possible harm in women. This finding cannot be ap-
propriately explained by the older age or the higher percent-
ageofpatientswithpreservedLVEFamongwomen,astherewas
no interactionwithageorLVEF.Possiblecontributors to thepo-
tentiallydetrimentaleffects inwomenmayincludesmallerbody
size, lowerbodyweight,differentbodycomposition, and lower
estimatedglomerular filtration rate, all ofwhichcouldcontrib-
ute to vasodilator overdose.
Early intensive and sustained vasodilation was associ-
ated with several adverse events, most notably an increased
rate of hypotension (8% vs 2%). Overall, the rate of hypoten-
sion was lower than observed with ularitide but higher than
observedwith serelaxin in 2 recent phase 3 trials.5,6Although
the lengthofhospitalizationwasnot significantlydifferentbe-
tween the 2 groups, adverse events related to the interven-
tion prolonged hospitalization in 10% of patients.
Protocol-guidedrapidup-titrationofACE inhibitors,ARBs,
or sacubitril-valsartan during the in-hospital period led to
higher percentage target doses at hospital discharge. How-
ever, themagnitude of the difference and the percentage tar-
get dose achievedwas lower than expected. Togetherwith in-
sights gained from 2 recent studies of sacubitril-valsartan in
the immediate postdischarge period using predefined outpa-
tientup-titrationvisits, the findingsof this studyhighlight the
importance of the immediate postdischarge period for pos-
sible improvements in long-termoutcomes.34,35Therather low
percentage of patients in this study attaining the high “target
doses” defined for chronic HF with reduced LVEF seem ex-
plained by 4 factors: first, the severity of AHF, which prohib-
itedachieving these targetdoses inmanypatientsdespitepro-
tocol-defined up-titration in the hospital; second, the inertia
of real-lifeoutpatientpostdischargecare, inwhichdosesofACE
inhibitors, ARBs, or sacubitril-valsartan are often not up-
titrated; third, the progressive nature of HF, as well as its co-
morbidities, requiringdose reductiondue to, for instance, hy-
potension,worsening renal function, and falls; and fourth, the
highprevalence of patientswithAHFwithpreservedLVEF, in
whom no target doses of ACE inhibitors, ARBs, or sacubitril-
valsartan are defined.1,2,36
Limitations
This study has several limitations. First, the results may not
apply to patients with severe renal dysfunction or with sys-
tolic blood pressure below 100 mm Hg, as they were ex-
cluded. Second, enrollment in this investigator-initiated trial
was slow, at least in part due to logistic and funding issues.
Because treatment of AHF generally remained unchanged
during the conduct of the study, findings should still apply to
current clinical practice.1,2,37,38 Third, this study had low sta-
tistical power for the analysis of subgroups and tests of inter-
action.Therefore, thesemustbe interpretedasexploratoryand
hypothesis generating. Fourth, the open-label design, which
wasmandated by the aim to test a strategy, not a single drug,
mayhave introducedabias in theunblindedassessmentofdys-
pnea at day 2 and day 6, but not in the primary end point of
all-causedeathorAHF rehospitalizationor its individual com-
ponents, as they were assessed by an independent clinical
events committeeblinded togroupassignment.Fifth,mostpa-
tients had gradual worsening of dyspnea prior to emergency
departmentpresentation. Focusingonpatientswith acuteon-
setofdyspneamight leadtodifferent results.3,4Sixth, theevent
rate observed in the usual care group was lower than as-
sumed in the sample size calculation. Seventh, the interven-
tion group combined the concepts of early initiation of vaso-
dilator therapy and accelerated initiation and up-titration of
chronicoralneurohormonal antagonist therapy.A factorial de-
sign separating the 2 couldhave allowedassessment of the ef-
fects of both individually.
Conclusions
AmongpatientswithAHF,a strategyofearly intensiveandsus-
tained vasodilation, compared with usual care, did not sig-
nificantly improve a composite outcome of all-cause mortal-
ity and AHF rehospitalization at 180 days.
Table 2. Adverse Events
Adverse Events





Hypokalemia <3.5 mmol/L 88 (23) 98 (25)
Worsening renal functiona 81 (21) 80 (20)
Headache 101 (26) 38 (10)
Dizziness 58 (15) 39 (10)
Hyperkalemia >5 mmol/L 41 (11) 28 (7)
Systolic arterial hypotensionb 29 (8) 9 (2)
Fall 14 (4) 7 (2)
Acute coronary syndrome 5 (1) 1 (<1)
Arrhythmia requiring therapy 2 (1) 3 (1)
Serious adverse events
All-cause rehospitalization 167 (44) 167 (42)
Rehospitalization for acute heart failurec 77 (20) 70 (18)
All-cause deaths 55 (14) 61 (15)
Prolongation of index hospitalization 39 (10) 23 (6)
Transfer to intensive care unit 14 (4) 16 (4)
Cardiopulmonary resuscitation 5 (1) 4 (1)
aWorsening renal function was defined as an increase in creatinine to more
than 30% of baseline.
bSystolic arterial hypotension was defined as systolic arterial pressure less than
80mmHg over 30minutes regardless of presence or absence of symptoms.
c Rehospitalization for acute heart failure defined as an unplanned admission to
a hospital with a length of stay of at least 24 hours because of symptoms
attributed to worsening of heart failure.2,27,28
Research Original Investigation Comprehensive Vasodilation vs Usual Care—Mortality and Rehospitalization for Heart Failure
2300 JAMA December 17, 2019 Volume 322, Number 23 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 02/19/2020
ARTICLE INFORMATION
Accepted for Publication:October 23, 2019.
Author Affiliations:Department of Cardiology and
Cardiovascular Research Institute Basel (CRIB),
University Hospital Basel, University of Basel, Basel,
Switzerland (Kozhuharov, Flores, Walter, Shrestha,
Gualandro, Sabti, Noveanu, Socrates, Ziller, Michou,
Pfister, Conen, Breidthardt, Mueller); GREAT
Research Network, Rome, Italy (Kozhuharov, Flores,
Walter, Shrestha, Gualandro, Sabti, Noveanu,
Socrates, Ziller, Michou, Pfister, Conen, Breidthardt,
Mueller); Queen Ioanna University Hospital Sofia,
Department of Cardiology, Medical University of
Sofia, Sofia, Bulgaria (Goudev); Department of
Cardiology, Kantonsspital St Gallen, St Gallen,
Switzerland (Maeder, Rickli); Department of
Internal Medicine, University Hospital Basel,
University of Basel, Basel, Switzerland (Walter,
Shrestha, Breidthardt); Heart Institute (INCOR),
University of Sao Paulo Medical School, Sao Paulo,
Brazil (Gualandro, de Oliveira Junior); Department
of General Internal and EmergencyMedicine,
Medical University Clinic of the University of Basel,
Kantonsspital Aarau, Aarau, Switzerland (Müller);
Medical Outpatient Department, University
Hospital Basel, University of Basel, Basel,
Switzerland (Socrates); Heart Institute, Hospital
Universitari Germans Trias i Pujol, CIBERCV,
Department of Medicine, Autonomous University
of Barcelona, Barcelona, Spain (Bayés-Genís);
Intensive Cardiac Care Unit, Cardiology
Department, Hospital de la Santa Creu i Sant Pau,
Biomedical Research Institute IIB-Sant Pau,
Autonomous University of Barcelona, Barcelona,
Spain (Sionis); Clinical Trial Unit, University Hospital
Basel, Basel, Switzerland (Simon); Department of
Cardiology, Luzerner Kantonsspital, Luzern,
Switzerland (Gujer, Kapos, Kobza, Erne);
Department of Internal Medicine, Kantonsspital
Obwalden, Sarnen, Switzerland (Gujer); University
Medical Center, Johannes Gutenberg University
Mainz, Mainz, Germany (Gori, Wenzel, Münzel);
Population Health Research Institute, McMaster
University, Hamilton, Ontario, Canada (Conen);
Department of Cardiology, University Hospital
Zurich, Zurich, Switzerland (Kapos).
Author Contributions:DrsWalter andMueller had
full access to all of the data in the study and take
responsibility for the integrity of the data and the
accuracy of the data analysis.
Concept and design: Flores, Noveanu, Ziller,
Michou, Gori, Breidthardt, Mueller.
Acquisition, analysis, or interpretation of data:
Kozhuharov, Goudev, Flores, Maeder, Walter,
Shrestha, Gualandro, Oliveira, Sabti, Müller,
Noveanu, Socrates, Ziller, Bayés-Genís, Sionis,
Simon, Gujer, Wenzel, Pfister, Conen, Kapos, Kobza,
Rickli, Breidthardt, Münzel, Erne, Mueller.
Drafting of the manuscript: Kozhuharov, Flores,
Walter, Noveanu, Socrates, Gujer, Gori, Mueller.
Critical revision of the manuscript for important
intellectual content: Kozhuharov, Goudev, Flores,
Maeder, Walter, Shrestha, Gualandro, Oliveira,
Sabti, Müller, Noveanu, Socrates, Ziller,
Bayés-Genís, Sionis, Simon, Michou, Wenzel,
Pfister, Conen, Kapos, Kobza, Rickli, Breidthardt,
Münzel, Erne, Mueller.
Statistical analysis:Walter, Sabti, Noveanu, Mueller.
Obtained funding:Noveanu, Socrates, Mueller.
Administrative, technical, or material support:
Kozhuharov, Goudev, Flores, Shrestha, Gualandro,
Noveanu, Socrates, Ziller, Simon, Gujer, Kapos,
Breidthardt, Mueller.
Supervision:Maeder, Oliveira, Mueller, Socrates,
Bayés-Genís, Sionis, Gori, Pfister, Kobza, Erne,
Mueller.
Conflict of Interest Disclosures:Dr Goudev
reported receiving personal fees (speaking
honoraria and advisory boardmembership) from
Pfizer, Novartis, AstraZeneca, and Amgen. Dr
Walter reported receiving grants from the Swiss
Heart Foundation and the Swiss Academy of
Medical Sciences. Dr Gualandro reported receiving
personal fees from Servier. Dr Wenzel reported
receiving personal fees fromNovartis, Bayer, the
German Federal Ministry for Education and
Research, and Abbott Vascular and nonfinancial
support from Servier. Dr Pfister reported receiving
personal fees fromNovartis, Vifor Pharma, and
Merck Sharp & Dohme and grants from Sanofi and
Boehringer Ingelheim. Dr Conen reported receiving
personal fees from Servier Canada. Dr Kobza
reported receiving grants from BiosenseWebster,
Biotronik, Medtronic, Abbott, SIS Medical, and
Boston Scientific. Dr Münzel reported being the
principal investigator of the DZHK (German Center
for Cardiovascular Research) Partner Site
Rhine-Main. Dr Mueller reported receiving grants
from the Swiss National Science Foundation, the
Swiss Heart Foundation, the Foundation for
Cardiovascular Research Basel, and the Stanley
Johnson Foundation; grants, personal fees, and
nonfinancial support from Roche Diagnostics,
Singulex, and Brahms; personal fees fromNovartis,
Cardiorentis, and Boehringer Ingelheim; and grants
and nonfinancial support from Abbott. No other
disclosures were reported.
Funding/Support: This study was supported by the
Swiss National Science Foundation, the Swiss Heart
Foundation, the University of Basel, the University
Hospital Basel, the Foundation for Cardiovascular
Research Basel, and the Stanley Thomas Johnson
Foundation.
Role of the Funder/Sponsor: The study funders
had no role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; or decision to submit
themanuscript for publication.
GALACTIC Investigators: Clinical site principal
investigators:University Hospital Basel, Basel,
Switzerland (Christian Mueller, MD, FESC); Lucerne
Cantonal Hospital, Lucerne, Switzerland (Paul Erne,
MD, FESC); Cantonal Hospital Aarau, Aarau,
Switzerland (Beat Müller, MD); Cantonal Hospital St
Gallen, St Gallen, Switzerland (Hans Rickli, MD, and
MichaMaeder, MD, PhD); Heart Institute (INCOR),
University of Sao Paulo Medical School, Sao Paulo,
Brazil (Mucio Tavares de Oliveira Jr, MD, PhD);
University Medicine Mainz, Mainz, Germany
(ThomasMünzel, MD); Hospital Universitari
Germans Trias i Pujol, Barcelona, Spain (Antoni
Bayés-Genís, MD); Hospital de la Santa Creu i Sant
Pau, Barcelona, Spain (Alessandro Sionis, MD);
University Hospital “Queen Ioanna,” Sofia, Bulgaria
(Assen Goudev, MD, PhD); Fifth Multifunctional
Hospital for Active Treatment, Sofia, Bulgaria
(Bojidar Dimov, MD). Additional investigators: Fifth
Multifunctional Hospital for Active Treatment,
Sofia, Bulgaria: Bojidar Dimov, MD; Department of
Cardiology, University Hospital Basel, University of
Basel, Switzerland: Sabine Hartwiger, MD, Nisha
Arenja, MD, Bettina Glatz, MD, Natascha Herr, SN,
Rahel Isenrich, MD, TaminaMosimann, MD, Raphael
Twerenbold, MD, Jasper Boeddinghaus, MD,
Thomas Nestelberger, MD, Christian Puelacher, MD,
Michael Freese, RN, Janine Vögele, RN, Kathrin
Meissner, RN, JasminMartin, MD, Ivo Strebel, PhD,
DesireeWussler, MD, Carmela Schumacher, MSc,
Stefan Osswald, MD, Fabian Vogt, MD, Jonas Hilti,
MD, Sara Barata, MD, Deborah Schneider, MD,
Jonas Schwarz, MD, and Brigitte Fitze, MD;
Cardiovascular Research Institute Basel (CRIB),
University Hospital Basel, Basel, Switzerland:
Sabine Hartwiger, MD, Nisha Arenja, MD, Bettina
Glatz, MD, Natascha Herr, SN, Rahel Isenrich, MD,
TaminaMosimann, MD, Raphael Twerenbold, MD,
Jasper Boeddinghaus, MD, Thomas Nestelberger,
MD, Christian Puelacher, MD, Michael Freese, RN,
Janine Vögele, RN, Kathrin Meissner, RN, Jasmin
Martin, MD, Ivo Strebel, PhD, DesireeWussler, MD,
Carmela Schumacher, MSc, Stefan Osswald, MD,
Fabian Vogt, MD, Jonas Hilti, MD, Sara Barata, MD,
Deborah Schneider, MD, Jonas Schwarz, MD, and
Brigitte Fitze, MD; Department of Cardiology,
Solothurner Spitäler, Kantonsspital Olten, Olten,
Switzerland: Nisha Arenja, MD; Department of
Laboratory Medicine, University Hospital Basel,
University of Basel, Basel, Switzerland: Katharina
Rentsch, PhD; Heart Institute (INCOR), University
of Sao Paulo Medical School, Sao Paulo, Brazil: Aline
Bossa, MSc, Sergio Jallad, MD, and Alexandre
Soeiro, MD; Institute for Medical Research, Sofia,
Bulgaria: Dimitar Georgiev; University Medical
Center, Johannes Gutenberg University Mainz,
Mainz, Germany: Thomas Jansen, MD, and Gabriele
Gebel, SN; Department of Cardiology, Luzerner
Kantonsspital, Luzern, Switzerland: Matthias
Bossard, MD, andMichael Christ, MD.
Data Sharing Statement: See Supplement 3.
REFERENCES
1. Yancy CW, JessupM, Bozkurt B, et al; Writing
Committee Members. 2013 ACCF/AHA guideline for
themanagement of heart failure: a report of the
American College of Cardiology Foundation/
American Heart Association Task Force on practice
guidelines. Circulation. 2013;128(16):e240-e327.
doi:10.1161/CIR.0b013e31829e8776
2. Ponikowski P, Voors AA, Anker SD, et al; ESC
Scientific Document Group. 2016 ESC guidelines for
the diagnosis and treatment of acute and chronic
heart failure: the Task Force for the Diagnosis and
Treatment of Acute and Chronic Heart Failure of the
European Society of Cardiology (ESC) developed
with the special contribution of the Heart Failure
Association (HFA) of the ESC. Eur Heart J. 2016;37
(27):2129-2200. doi:10.1093/eurheartj/ehw128
3. Cotter G, Metzkor E, Kaluski E, et al. Randomised
trial of high-dose isosorbide dinitrate plus low-dose
furosemide versus high-dose furosemide plus
low-dose isosorbide dinitrate in severe pulmonary
oedema. Lancet. 1998;351(9100):389-393. doi:10.
1016/S0140-6736(97)08417-1
4. Sharon A, Shpirer I, Kaluski E, et al. High-dose
intravenous isosorbide-dinitrate is safer and better
than bi-PAP ventilation combined with
conventional treatment for severe pulmonary
edema. J Am Coll Cardiol. 2000;36(3):832-837. doi:
10.1016/S0735-1097(00)00785-3
Comprehensive Vasodilation vs Usual Care—Mortality and Rehospitalization for Heart Failure Original Investigation Research
jama.com (Reprinted) JAMA December 17, 2019 Volume 322, Number 23 2301
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 02/19/2020
5. Packer M, O’Connor C, McMurray JJV, et al;
TRUE-AHF Investigators. Effect of ularitide on
cardiovascular mortality in acute heart failure.
N Engl J Med. 2017;376(20):1956-1964. doi:10.
1056/NEJMoa1601895
6. Metra M, Teerlink JR, Cotter G, et al;
RELAX-AHF-2 Committees Investigators. Effects of
serelaxin in patients with acute heart failure. N Engl
J Med. 2019;381(8):716-726. doi:10.1056/
NEJMoa1801291
7. O’Connor CM, Starling RC, Hernandez AF, et al.
Effect of nesiritide in patients with acute
decompensated heart failure. N Engl J Med. 2011;
365(1):32-43. doi:10.1056/NEJMoa1100171
8. Breidthardt T, NoveanuM, Potocki M, et al.
Impact of a high-dose nitrate strategy on cardiac
stress in acute heart failure: a pilot study. J InternMed.
2010;267(3):322-330. doi:10.1111/j.1365-2796.2009.
02146.x
9. Gogia H, Mehra A, Parikh S, et al. Prevention of
tolerance to hemodynamic effects of nitrates with
concomitant use of hydralazine in patients with
chronic heart failure. J Am Coll Cardiol. 1995;26(7):
1575-1580. doi:10.1016/0735-1097(95)00368-1
10. Cohn JN, Johnson G, Ziesche S, et al.
A comparison of enalapril with hydralazine-
isosorbide dinitrate in the treatment of chronic
congestive heart failure. N Engl J Med. 1991;325(5):
303-310. doi:10.1056/NEJM199108013250502
11. Cohn J, Archibald D, Ziesche S, et al. Effect of
vasodilator therapy onmortality in chronic
congestive heart failure: results of a veterans
administration cooperative study. Surv Anesthesiol.
1987;31(1):53. doi:10.1097/00132586-198702000-
00050
12. Packer M, Poole-Wilson PA, Armstrong PW,
et al; ATLAS Study Group. Comparative effects of
low and high doses of the angiotensin-converting
enzyme inhibitor, lisinopril, on morbidity and
mortality in chronic heart failure. Circulation. 1999;
100(23):2312-2318. doi:10.1161/01.CIR.100.23.2312
13. KonstamMA, Neaton JD, Dickstein K, et al;
HEAAL Investigators. Effects of high-dose versus
low-dose losartan on clinical outcomes in patients
with heart failure (HEAAL study): a randomised,
double-blind trial. Lancet. 2009;374(9704):1840-
1848. doi:10.1016/S0140-6736(09)61913-9
14. Jiménez Víbora E, Aresté N, Salgueira M, et al;
World Medical Association. World Medical
Association Declaration of Helsinki: ethical
principles for medical research involving human
subjects. JAMA. 2013;310(20):2191-2194. doi:10.
1001/jama.2013.281053
15. Schulz KF, Altman DG, Moher D; CONSORT
Group. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised
trials. BMJ. 2010;340:c332-c332. doi:10.1136/bmj.
c332
16. Packer M, McMurray JJVV, Desai AS, et al;
PARADIGM-HF Investigators and Coordinators.
Angiotensin receptor neprilysin inhibition
compared with enalapril on the risk of clinical
progression in surviving patients with heart failure.
Circulation. 2015;131(1):54-61. doi:10.1161/
CIRCULATIONAHA.114.013748
17. McMurray JJV, Packer M, Desai AS, et al;
PARADIGM-HF Investigators and Committees.
Angiotensin-neprilysin inhibition versus enalapril in
heart failure. N Engl J Med. 2014;371(11):993-1004.
doi:10.1056/NEJMoa1409077
18. Pocock SJ, Simon R. Sequential treatment
assignment with balancing for prognostic factors in
the controlled clinical trial. Biometrics. 1975;31(1):
103-115. doi:10.2307/2529712
19. Jordan RA, Seith L, Henry DA, Wilen MM,
Franciosa JA. Dose requirements and
hemodynamic effects of transdermal nitroglycerin
compared with placebo in patients with congestive
heart failure. Circulation. 1985;71(5):980-986. doi:
10.1161/01.CIR.71.5.980
20. JohnsonW, Omland T, Hall C, et al.
Neurohormonal activation rapidly decreases
after intravenous therapy with diuretics and
vasodilators for class IV heart failure. J AmColl Cardiol.
2002;39(10):1623-1629. doi:10.1016/S0735-1097(02)
01814-4
21. NieminenMS, Brutsaert D, Dickstein K, et al;
EuroHeart Survey Investigators; Heart Failure
Association, European Society of Cardiology.
EuroHeart Failure Survey II (EHFS II): a survey on
hospitalized acute heart failure patients:
description of population. Eur Heart J. 2006;27
(22):2725-2736. doi:10.1093/eurheartj/ehl193
22. Pang PS, Cleland JGF, Teerlink JR, et al; Acute
Heart Failure Syndromes International Working
Group. A proposal to standardize dyspnoea
measurement in clinical trials of acute heart failure
syndromes: the need for a uniform approach. Eur
Heart J. 2008;29(6):816-824. doi:10.1093/
eurheartj/ehn048
23. Mueller C, Laule-Kilian K, Schindler C, et al.
Cost-effectiveness of B-type natriuretic peptide
testing in patients with acute dyspnea. Arch Intern
Med. 2006;166(10):1081-1087. doi:10.1001/
archinte.166.10.1081
24. Voors AA, OuwerkerkW, Zannad F, et al.
Development and validation of multivariable
models to predict mortality and hospitalization in
patients with heart failure. Eur J Heart Fail. 2017;19
(5):627-634. doi:10.1002/ejhf.785
25. OuwerkerkW, Voors AA, Zwinderman AH.
Factors influencing the predictive power of models
for predicting mortality and/or heart failure
hospitalization in patients with heart failure. JACC
Heart Fail. 2014;2(5):429-436. doi:10.1016/j.jchf.
2014.04.006
26. Pocock SJ, McMurray JJV, Collier TJ. Statistical
controversies in reporting of clinical trials: part 2 of
a 4-part series on statistics for clinical trials. J Am
Coll Cardiol. 2015;66(23):2648-2662. doi:10.1016/j.
jacc.2015.10.023
27. Vader JM, LaRue SJ, Stevens SR, et al. Timing
and causes of readmission after acute heart failure
hospitalization—insights from the Heart Failure
Network trials. J Card Fail. 2016;22(11):875-883.
doi:10.1016/j.cardfail.2016.04.014
28. Hicks KA, Tcheng JE, Bozkurt B, et al; American
College of Cardiology; American Heart Association.
2014 ACC/AHA key data elements and definitions
for cardiovascular endpoint events in clinical trials:
a report of the American College of
Cardiology/American Heart Association Task Force
on Clinical Data Standards (Writing Committee to
Develop Cardiovascular Endpoints Data Standards).
Circulation. 2015;132(4):302-361. doi:10.1161/CIR.
0000000000000156
29. Felker GM, Lee KL, Bull DA, et al; NHLBI Heart
Failure Clinical Research Network. Diuretic
strategies in patients with acute decompensated
heart failure. N Engl J Med. 2011;364(9):797-805.
doi:10.1056/NEJMoa1005419
30. PeacockWF IV, DeMarco T, Fonarow GC, et al;
ADHERE Investigators. Cardiac troponin and
outcome in acute heart failure. N Engl J Med. 2008;
358(20):2117-2126. doi:10.1056/NEJMoa0706824
31. Testani JM, Chen J, McCauley BD, Kimmel SE,
Shannon RP. Potential effects of aggressive
decongestion during the treatment of
decompensated heart failure on renal function and
survival. Circulation. 2010;122(3):265-272. doi:10.
1161/CIRCULATIONAHA.109.933275
32. Breidthardt T, Weidmann ZM, Twerenbold R,
et al. Impact of haemoconcentration during acute
heart failure therapy onmortality and its
relationship with worsening renal function. Eur J
Heart Fail. 2017;19(2):226-236. doi:10.1002/ejhf.667
33. Bart BA, Goldsmith SR, Lee KL, et al; Heart
Failure Clinical Research Network. Ultrafiltration in
decompensated heart failure with cardiorenal
syndrome. N Engl J Med. 2012;367(24):2296-2304.
doi:10.1056/NEJMoa1210357
34. Wachter R, Fonseca AF, Balas B, et al.
Real-world treatment patterns of
sacubitril/valsartan: a longitudinal cohort study in
Germany. Eur J Heart Fail. 2019;21(5):588-597. doi:
10.1002/ejhf.1465
35. Velazquez EJ, Morrow DA, DeVore AD, et al;
PIONEER-HF Investigators. Angiotensin-neprilysin
inhibition in acute decompensated heart failure.
N Engl J Med. 2019;380(6):539-548. doi:10.1056/
NEJMoa1812851
36. Solomon SD, McMurray JJV, Anand IS, et al;
PARAGON-HF Investigators and Committees.
Angiotensin-neprilysin inhibition in heart failure
with preserved ejection fraction.N Engl J Med.
2019;381(17):1609-1620. doi:10.1056/
NEJMoa1908655
37. Mebazaa A, YilmazMB, Levy P, et al.
Recommendations on pre-hospital and early
hospital management of acute heart failure:
a consensus paper from the Heart Failure
Association of the European Society of Cardiology,
the European Society of EmergencyMedicine and
the Society of Academic Emergency
Medicine—short version. Eur Heart J. 2015;36(30):
1958-1966. doi:10.1093/eurheartj/ehv066
38. Mueller C, Christ M, Cowie M, et al; Acute Heart
Failure Study Group of the ESC Acute
Cardiovascular Care Association. European Society
of Cardiology–Acute Cardiovascular Care
Association position paper on acute heart failure:
a call for interdisciplinary care. Eur Heart J Acute
Cardiovasc Care. 2017;6(1):81-86. doi:10.1177/
2048872615593279
Research Original Investigation Comprehensive Vasodilation vs Usual Care—Mortality and Rehospitalization for Heart Failure
2302 JAMA December 17, 2019 Volume 322, Number 23 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 02/19/2020
